Drug Profile
Research programme: MOSPD2 monoclonocal antibodies - VBL Therapeutics
Alternative Names: Anti-MOSPD2 monoclonal antibodies; VB-600 monoclonal antibody seriesLatest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator VBL Therapeutics
- Class Anti-inflammatories; Antirheumatics; Hepatoprotectants; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Non-alcoholic steatohepatitis; Rheumatoid arthritis
- No development reported Inflammation; Multiple sclerosis
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Inflammation in Israel (Parenteral)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Multiple-sclerosis in Israel (Parenteral)
- 12 Oct 2020 VBL Therapeutics has patent protection for anti-MOSPD2 monoclonal antibodies for inflammatory and autoimmune conditions in Europe